The US Food and Drug Administration has granted full approval to daraxonrasib, the first drug of its kind cleared for metastatic pancreatic cancer — a disease whose most common form carries a five-year survival rate of just 8%. In clinical trials, the treatment nearly doubled survival times for patients with advanced disease compared with the standard of care, according to a discussion on Chemistry World's Chemical Breakdown podcast.

The drug targets RAS, a signalling protein that drives cell division and has resisted conventional medicinal chemistry for decades. Phillip Broadwith, Chemistry World's business editor, explained why: RAS lacks the binding pockets that small molecules exploit. "It just has quite fluffy surfaces and it interacts with other proteins over large surface areas rather than at very specific sites," he said.

Daraxonrasib belongs to a class of molecules known as molecular glues. Rather than blocking a binding site, these compounds slip between protein–protein interactions and either strengthen or disrupt them. In this case, the glue makes RAS stick more tightly to a partner protein, breaking the signalling cascade that drives uncontrolled proliferation.

Measured benefit, honest limits

The trial data warrant scrutiny. Patients treated with daraxonrasib live on average a few months longer than those on standard treatment — a measured, modest gain, not a cure. Broadwith noted evidence that rapidly dividing cancer cells can mutate around the interaction and develop resistance. "That's an average. Some people live significantly longer, some people perhaps a little bit less," he said.

One clear workflow advantage: because daraxonrasib is a relatively small molecule, it comes as a tablet taken at home, rather than the intravenous infusions typical of chemotherapy regimens. That difference shapes quality of life during the additional months.

The drug also differs from earlier RAS-targeting agents. Existing approvals work only against very specific RAS mutants. Daraxonrasib appears to block multiple RAS mutations, which means it also suppresses RAS signalling in healthy tissue — but because normal cell division runs far slower than in tumours, those side effects tend to be manageable, according to the podcast discussion. The broader coverage opens the possibility of use in other cancer types.

Pricing remains unresolved. Broadwith expects the drug to be expensive at launch, and US insurers and state healthcare systems will still need to negotiate cost-effectiveness terms before reimbursement is settled. But as a small molecule, it could become substantially cheaper once generics arrive in seven or eight years — unlike biologics, where even biosimilars carry complex manufacturing costs.

The approval also signals momentum for protein-manipulation strategies broadly. Degastrant, the first PROTAC — a molecule that glues a target protein to degradation machinery — was approved in May. Broadwith predicts such approaches will become "much, much more prevalent" in the next few years, mostly in oncology.

Spectroscopy reads a thousand-year-old textile

The second feature examines the Bayeux Tapestry, now on display at the British Museum on loan from France's Bayeux Museum during renovation of its permanent home. The 70-metre linen embroidery, worked in wool, depicts the events preceding the Norman conquest of England and is nearly 1,000 years old — one of very few 11th-century fabric artefacts to survive, and one that endured centuries of war in Normandy.

Conservation science is now answering questions that documents cannot. Linen is hygroscopic: its cellulose hydroxyl groups hydrogen-bond to water, and fluctuating humidity breaks and reforms those bonds, causing wrinkling, shrinkage and tears. Researchers ran a long-term monitoring experiment, capturing a one-minute exposure photograph every six minutes over months, and correlated dimensional change with seasonal museum conditions.

The finding has direct budget implications for the new Bayeux Museum. The tapestry tolerates small humidity swings — roughly between 50 and 60% — but suffers under large ones. Curators therefore do not need to hold temperature and humidity absolutely constant; they can let conditions cycle gently with the seasons, cutting heating and moisture-control costs in a large new building.

Dye analysis has produced a counterintuitive result. Restoration work in the 1860s and 1870s replaced decayed threads with wool dyed using early synthetic dyes — and those synthetic dyes have faded faster than the original thousand-year-old colourants, a measured indictment of the nascent chemical industry's products. The original palette is well characterised: madder dyes (anthraquinones) for reds, weld (flavonoids) for yellows, and woad and indigo-type dyes for blues, all plant-derived.

Because the reverse of the tapestry escaped light exposure, its colours remain vivid. Conservators can photograph the back, match each thread to its counterpart on the front, and combine that with spectroscopic analysis to reconstruct the original appearance — largely without destructive sampling, since modern spectroscopy is sufficiently advanced.

That reconstruction carries historical weight. A painted copy commissioned by the Society of Antiquaries in the mid-19th century matches the colours visible on the reverse today, indicating that most fading occurred in the roughly 150 years since display began — not during the previous 850 years, when the tapestry was shown perhaps once a year in the dim, stained-glass-filtered light of Bayeux Cathedral. Modern LED lighting should slow further degradation.

Thread analysis is also rewriting iconography. The famous image of Harold with an arrow in his eye appears to be a later restoration: holes in the fabric suggest something was originally there, possibly a spear, and restorers can distinguish ancient from modern threads to confirm the addition.

Open questions remain. The exact site of manufacture — probably England, near Canterbury — could be pinned down by DNA testing the wool and comparing it against medieval samples, which might in turn clarify the patron, with Bishop Odo, William the Conqueror's brother-in-law, the leading candidate. The British Museum exhibition runs until 2027, with tickets currently sold out and further releases expected in October — and the analytical campaign on the textile continues.